Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urine Cytology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Urine Cytology. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2016-004269-14 Sponsor Protocol Number: HP002-001 Start Date*: 2018-05-07
    Sponsor Name:Hamlet Pharma AB
    Full Title: A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery
    Medical condition: Non-muscle invasive bladder cancer awaiting transurethral surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001791-36 Sponsor Protocol Number: 310781 Start Date*: 2008-01-24
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo onc...
    Medical condition: Vasomotor symptoms (hot flushes)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000138-37 Sponsor Protocol Number: PERISCOPE Start Date*: 2013-09-25
    Sponsor Name:NKI-AvL
    Full Title: Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy
    Medical condition: Gastric cancer with peritoneal carcinomatosis or positive peritoneal cytology.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10017812 Gastric neoplasms malignant HLT
    16.0 10042613 - Surgical and medical procedures 10067093 Intraperitoneal hyperthermic chemotherapy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001028-32 Sponsor Protocol Number: CIVI/2018/NH-01 Start Date*: 2020-09-09
    Sponsor Name:CHU DE NIMES
    Full Title: Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable,...
    Medical condition: The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002760-16 Sponsor Protocol Number: 04/QO603/42 HEXVIX Start Date*: 2005-01-12
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bl...
    Medical condition: Superficial Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000059-38 Sponsor Protocol Number: 21810 Start Date*: 2021-11-17
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women.
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001888-40 Sponsor Protocol Number: DEP NHL-P 001.A Start Date*: 2006-07-24
    Sponsor Name:Mundipharma Research Ltd.
    Full Title: A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with agg...
    Medical condition: Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10029547 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003159-44 Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-1 Start Date*: 2018-09-27
    Sponsor Name:Spanish Oncology Genitourinary Group
    Full Title: Phase II trial of durvalumab (Medi4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach
    Medical condition: Localized muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10022878 Invasive bladder cancer stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004855-34 Sponsor Protocol Number: 21652 Start Date*: 2021-11-25
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NO (Completed) PT (Completed) SK (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004908-33 Sponsor Protocol Number: 21651 Start Date*: 2021-10-18
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038604 - Reproductive system and breast disorders 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) IT (Completed) HU (Completed) NL (Completed) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021718-41 Sponsor Protocol Number: 214868-004-03 Start Date*: 2011-03-03
    Sponsor Name:Allergan Ltd
    Full Title: A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence
    Medical condition: To evaluate the safety and efficacy of AGN-214868 compared with placebo in the treatment of patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003751-42 Sponsor Protocol Number: ICH-013-UroNEOadI Start Date*: 2022-01-25
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Randomized phase III clinical trial of Neo-Adjuvant Intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms.
    Medical condition: Patients with primary treatment-naïve vesical neoplasms.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10046702 Urogenital neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017396-19 Sponsor Protocol Number: CA184104 Start Date*: 2011-04-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subje...
    Medical condition: Stage IV/Recurrent Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DE (Completed) BE (Completed) GB (Completed) AT (Completed) NL (Completed) DK (Completed) CZ (Completed) PT (Completed) IE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000173-21 Sponsor Protocol Number: (no code number allocated) Start Date*: 2005-11-28
    Sponsor Name:Dieter Hoelzer, MD,PhD
    Full Title: A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCYTE® (CYTARABINE LIPOSOME INJECTION) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR H...
    Medical condition: Acute lymphoblastic leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000135-31 Sponsor Protocol Number: TABENETOC Start Date*: 2022-01-12
    Sponsor Name:Region Östergötland
    Full Title: The Effect of tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy – A randomized pilot study
    Medical condition: Epithelial ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000850-48 Sponsor Protocol Number: CA184-156 Start Date*: 2012-06-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease ...
    Medical condition: Extensive Stage Disease Small Cell Lung Cancer (ED-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) IT (Completed) SE (Completed) DE (Completed) CZ (Completed) AT (Completed) GB (Completed) PT (Completed) HU (Completed) ES (Completed) NL (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001236-28 Sponsor Protocol Number: R39_21_01 Start Date*: 2022-11-22
    Sponsor Name:Fidia Farmaceutici S.p.A.
    Full Title: A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG-unresponsive Carcinoma in Si...
    Medical condition: BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007400 Carcinoma in situ of the bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004743-22 Sponsor Protocol Number: FFR30006 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc...
    Medical condition: Vasomotor/Idiopathic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004744-43 Sponsor Protocol Number: FFR30007 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc...
    Medical condition: Vasomotor/Idiopathic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004206-25 Sponsor Protocol Number: 1839IL/0711 Start Date*: 2005-03-02
    Sponsor Name:AstraZeneca AB
    Full Title: A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAP...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA